HEALTH AND HUMAN SERVICES > NATIONAL INSTITUTES OF HEALTH > NATIONAL CANCER INSTITUTE
Teaming Partner Requirements
541990 All Other Professional, Scientific, and Technical Services
General Details on this Teaming Opportunity
National Institutes of Health, Bethesda, MD 20892 and Centers for Disease Control and Prevention, Atlanta, GA 30305 are soliciting proposals from small business concerns that possess the research and development (R&D) expertise to conduct innovative research that will contribute toward meeting the program objectives of the agencies. The SBIR Phase I Contract Solicitation will be available ONLY via electronic means. Printed copies of the Solicitation will not be distributed. Potential offerors are encouraged to check the NIH Small Business Research Funding Opportunities Web site for updates on the program. Any updates or corrections to the Solicitation will be posted there. The purposes of the SBIR program are to: (a) stimulate technological innovation in the private sector; (b) strengthen the role of small business in meeting Federal research/research & development (R/R&D) needs; (c) increase the commercial application of Federally-supported research results; (d) foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns; and improve the return on investment from Federally-funded research for economic and social benefits to the Nation. For purposes of the SBIR program, a small business concern is any business concern that, on the date of award, (1) is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor; (2) is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there can be no more than 49 percent participation by foreign business entities in the joint venture; (3) is at least 51 percent owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the United States; or is owned and controlled by another (one) small business concern that is itself at least 51 percent owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the United States; AND (4) has, including its affiliates, no more than 500 employees. RNAi Cancer Therapeutics using Nanotechnology; Development of Human Tissue Culture Systems that Mimic the Tumor Microenvironment; Development of Companion Diagnostics: Enabling Precision Medicine in Cancer Therapy; Development of CTC Isolation Technologies Enabling Downstream Single Cell Molecular Analysis; Wound Healing Preparations Incorporating Nitric Oxide-Releasing Materials (NIH Technology Transfer); Test to Predict Effectiveness of Docetaxel Treatment for Prostate Cancer (NIH Technology Transfer); Technology to Generate Anti-Peptide Capture Reagents for Affinity-Enriched Proteomic Studies; High Quality Cancer-Related Standards for Metabolomics Research; Chemically Defined Glycan Libraries for Reference Standards and Glycomics Research (Joint NCI-NIGMS Program); Real-Time Integration of Sensor and Self-Report Data for Clinical and Research Applications; Development of Radiation Modulators for Use During Radiotherapy; Novel Imaging Agents to Expand the Clinical Toolkit for Cancer Diagnosis, Staging, and Treatment; Innovative Radiation Sources for Advanced Radiotherapy Equipment. NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS): Visualizing Knowledge about Human Health and the Pathways of Translation; Biomarker Study for Creatine Transporter Defect Disorders; Automated Instrument to Clean Microtiter Plates; Assay Development for High-Throughput Screening of Chemicals of Toxicological Concern. NATIONAL HEART, LUNG AND BLOOD INSTITUTE (NHLBI): New Methods to Detect and Assess Myocardial Fibrosis; Evaluating Obstructive Sleep Apnea Dental Device Treatment Compliance; Improving Safety and Efficacy of Red Blood Cells for Transfusion; Dedicated Pediatric Cardiac MRI Receive Coils; MRI Myocardial Biopsy Forceps; Passive MRI Guidewire; Transthoracic Cardiac Access Ports and Closure Devices; Bioabsorbable Stents for Pediatric Pulmonary Artery Stenosis and Aortic Coarctation; Fluorescent Nanodiamonds for In Vitro and In Vivo Biological Imaging. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID): Aerosolized Delivery of Anti-Tubercular Drugs; Development of Long-Acting Formulations of HIV Anti-Retrovirals; Improved Formulations for Approved First and Second line anti-Tuberculosis (TB) Drugs; Integrated Multiplex Medical Diagnostics Platforms for Infectious Diseases. EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT (NICHD): Neural Interfaces: Improving Functional Outcomes. NATIONAL INSTITUTE ON DRUG ABUSE (NIDA): A Mobile Application to Help Patients Take their Pill Medications as Prescribed: Improving Medication Adherence; Products for at-home Deactivation of Psychoactive Prescription Medicines; Development of Predictive in vivo Screening Systems for Phenotypic Drug Discovery for Smoking Cessation; Video Game Targeting Relapse Prevention in Youth with Substance Use Disorders. CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) - CENTER FOR GLOBAL HEALTH (CGH): Diagnostic Needs for Neglected Tropical Diseases (NTD) Programs; Rapid Screening Tests to Prevent Congenital Infections and Ensure Blood Safety; Development of Diagnostic Tests for Strongyloidiasis and Schistosomiasis. NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES (NCBDDD): Improving Data, Improving Care, Making it Count; Smartphone Application for Global Birth Defects Surveillance. NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION (NCCDPHP): A Mobile Phone Application ("App") for Advancing Teen Pregnancy Prevention. NATIONAL CENTER FOR EMERGING ZOONOTIC AND INFECTIOUS DISEASES (NCEZID): Development of Nanoparticle Dengue Diagnostic Tests; Development of Tests in a Standardized Kit Format for Diagnosis of Arboviral Infections in Resource-Limited, Primary Health Care Setting; Reducing Antimicrobial Resistance through Improved use of Laboratory Testing Information in Healthcare Facilities. NATIONAL CENTER FOR HIV/AIDs, VIRAL HEPATITIS, STD, AND TB PREVENTION (NCHHSTP): Development of Biomedical Devices to Elicit Durable Protective Immunity against HIV; Development of a Portable Multiplex Assay for Determination of Recent HIV-1 Infection; Testing the Efficacy of Combination HIV Prevention Strategies in Nonhuman Primates. NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES (NCIRD): Development of an Inactivated Rotavirus Vaccine for Use in Global Immunization; Thermostable Dry Measles Vaccine Formulation for Sublingual Administration. OFFICE OF PUBLIC HEALTH PREPAREDNESS AND RESPONSE (OPHPR): Improved Methods for Collection, Preservation, and Transportation of Biological Specimens.
Learn more about this Teaming Opportunity published on GovWin - the professional network where businesses exchange opportunities, resources, and information, to win more business, expand capabilities, and increase profitability.
Follow new Business Opportunities, Resources, and Assets on Twitter:
Resource Availability and Demands
New Corporate and Individual Members